Publications by authors named "Misti Jain"

Ex vivo human tumor models have emerged as promising, yet complex tools to study cancer immunotherapy response dynamics. Here, we present a strategy that integrates empirical data from an ex vivo human system with computational models to interpret the response dynamics of a clinically prescribed PD-1 inhibitor, nivolumab, in head and neck squamous cell carcinoma (HNSCC) biopsies (N = 50). Using biological assays, we show that drug-induced variance stratifies samples by T helper type 1 (Th1)-related pathways.

View Article and Find Full Text PDF

Colorectal cancer is the third major cause of cancer-related mortality worldwide. The upward trend in incidence and mortality rates, poor sensitivity to conventional therapies and a dearth of early diagnostic parameters pose a huge challenge in the management of colorectal cancer in India. Due to the high level of genetic diversity present in the Indian population, unraveling the genetic contributions toward pathogenesis is key for understanding the etiology of colorectal cancer and in reversing this trend.

View Article and Find Full Text PDF
Article Synopsis
  • KRAS mutation status is crucial in determining whether metastatic colorectal carcinoma (mCRC) patients can benefit from EGFR-targeted therapies like cetuximab, with mutant KRAS patients often excluded from these treatments.* -
  • The study utilized an innovative platform called CANscript to test the effectiveness of EGFR-targeted drugs on live tumor tissues from mCRC patients, finding that the majority of tumors did not respond to cetuximab, regardless of KRAS status.* -
  • The research identified that the resistance to cetuximab in non-responsive tumors was linked to EGFR ligand expression and altered signaling pathways, suggesting that targeting these pathways could improve treatment outcomes for resistant patients.*
View Article and Find Full Text PDF

The PI3K/AKT/mTOR pathway is an important signaling axis that is perturbed in majority of cancers. Biomarkers such as pS6RP, GLUT1, and tumor FDG uptake are being evaluated in patient stratification for mTOR pathway inhibitors. In the absence of a clear understanding of the underlying mechanisms in tumor signaling, the biomarker strategy for patient stratification is of limited use.

View Article and Find Full Text PDF

The diagnostic and prognostic significance of cathepsin B (CTSB) and L (CTSL) is well documented for solid tumors. However, their significance in acute leukemias is lacking. This study was planned to investigate expression and significance of these proteases in peripheral blood mononuclear cells (PBMCs) of patients with pediatric acute myeloid leukemia (AML).

View Article and Find Full Text PDF

Dipetidyl-peptidase III is a metallopeptidase involved in a number of physiological processes and its expression has been reported to increase with the histological aggressiveness of human ovarian primary carcinomas. Because no information regarding the regulation of its expression was available, experiments were designed to clone, define and characterize the promoter region of the human dipeptidyl-peptidase III (DPP-III) gene. In this study, we cloned a 1038 bp 5'-flanking DNA fragment of the human DPP-III gene for the first time and demonstrated strong promoter activity in this region.

View Article and Find Full Text PDF